Methoxy Polyethylene Glycol-Epoetin Beta (Mircera): Patient Guide
Methoxy polyethylene glycol-epoetin beta, also called Mircera, is a long-acting medicine that helps the body make more red blood cells. It is used to treat anemia caused by chronic kidney disease or by chemotherapy in adults. It is prescribed and monitored by a healthcare professional because the correct dose depends on blood-test results and other health factors.
This medicine can treat certain types of anemia, but it can also raise blood pressure and increase the risk of blood clots, heart problems, or stroke. Use it only as prescribed and keep all blood-test and monitoring appointments.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- B03XA03
- RxNorm
- 729596
- Generic
- Methoxy Polyethylene Glycol-Epoetin Beta
- Class
- atc-b03
- Brands
- Mircera
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe, solution
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 0.6 mcg weekly
- Maximum
- consult physician
- Frequency
- once weekly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.8 mcg/kg weekly
- Maximum
- consult physician
- Frequency
- once weekly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.6 mcg weekly
- Maximum
- consult physician
- Frequency
- once weekly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
11 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring and maternal blood pressure
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring and maternal blood pressure
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingnot recommended
discontinue breastfeeding or avoid drug
monitor infant for anemia
pediatric_age
under 5 yearsnot established
safety and efficacy not established in children under 5 years
hemoglobin and blood pressure monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pediatric_age
5 to 18 yearsuse with caution
use only if benefits outweigh risks
regular hemoglobin and blood pressure monitoring
Use with caution and monitor for adverse effects.
geriatric
over 65 yearsno specific adjustment needed
standard dosing with individual titration
regular hemoglobin and blood pressure monitoring
renal_impairment
mild to moderatedose titration required
initiate at lower dose and titrate to target hemoglobin
regular hemoglobin and blood pressure monitoring
renal_impairment
severedose titration required
initiate at lower dose and titrate to target hemoglobin
regular hemoglobin and blood pressure monitoring
hepatic_impairment
mild to moderateno specific adjustment recommended
use with caution and monitor response
regular hemoglobin monitoring
Use with caution and monitor for adverse effects.
hepatic_impairment
severeuse with caution
use only if benefits outweigh risks
regular hemoglobin and liver function monitoring
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
Initial FDA approval for Mircera
Drug class
ATC classification B03XA02
Common uses
Main therapeutic indication
Mechanism of action
Primary pharmacodynamic action
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy